Management of hypertension with fixed-dose triple-combination treatments

Benjamin J. Epstein, Niren K. Shah, Nancy Hart

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The objective of this review is to evaluate the role of fixed-dose triple-combination therapy for the management of hypertension. An assessment of clinical trials showed that half the patients with hypertension have uncontrolled blood pressure (BP), with underlying factors including therapeutic inertia and poor patient adherence. Many patients will require three antihypertensive agents to achieve BP goals, and current guidelines recommend combining drugs with complementary mechanisms of action. Three single-pill triple-combination treatments are available and each includes an agent affecting the renin-angiotensin-aldosterone pathway (either a direct renin inhibitor or an angiotensin II receptor blocker) in combination with a calcium channel blocker and diuretic. These triple-combination therapies consistently demonstrated significantly greater BP reduction relative to the component dual combinations, with BP reductions documented across a range of patient populations. Triple-combination treatments were well tolerated in all clinical trials reviewed. The use of single-pill, triple-combination antihypertensive therapy has been shown to be an effective, well-tolerated, and convenient treatment strategy that can help patients achieve BP control.

Original languageEnglish (US)
Pages (from-to)246-259
Number of pages14
JournalTherapeutic Advances in Cardiovascular Disease
Volume7
Issue number5
DOIs
StatePublished - Jan 1 2013

Fingerprint

Hypertension
Blood Pressure
Renin
Antihypertensive Agents
Therapeutics
Clinical Trials
Angiotensin Receptor Antagonists
Angiotensins
Calcium Channel Blockers
Patient Compliance
Aldosterone
Diuretics
Guidelines
Pharmaceutical Preparations
Population

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Management of hypertension with fixed-dose triple-combination treatments. / Epstein, Benjamin J.; Shah, Niren K.; Hart, Nancy.

In: Therapeutic Advances in Cardiovascular Disease, Vol. 7, No. 5, 01.01.2013, p. 246-259.

Research output: Contribution to journalArticle

@article{73259da827fb42008bd08d9d04577239,
title = "Management of hypertension with fixed-dose triple-combination treatments",
abstract = "The objective of this review is to evaluate the role of fixed-dose triple-combination therapy for the management of hypertension. An assessment of clinical trials showed that half the patients with hypertension have uncontrolled blood pressure (BP), with underlying factors including therapeutic inertia and poor patient adherence. Many patients will require three antihypertensive agents to achieve BP goals, and current guidelines recommend combining drugs with complementary mechanisms of action. Three single-pill triple-combination treatments are available and each includes an agent affecting the renin-angiotensin-aldosterone pathway (either a direct renin inhibitor or an angiotensin II receptor blocker) in combination with a calcium channel blocker and diuretic. These triple-combination therapies consistently demonstrated significantly greater BP reduction relative to the component dual combinations, with BP reductions documented across a range of patient populations. Triple-combination treatments were well tolerated in all clinical trials reviewed. The use of single-pill, triple-combination antihypertensive therapy has been shown to be an effective, well-tolerated, and convenient treatment strategy that can help patients achieve BP control.",
author = "Epstein, {Benjamin J.} and Shah, {Niren K.} and Nancy Hart",
year = "2013",
month = "1",
day = "1",
doi = "10.1177/1753944713498638",
language = "English (US)",
volume = "7",
pages = "246--259",
journal = "Therapeutic Advances in Cardiovascular Disease",
issn = "1753-9447",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Management of hypertension with fixed-dose triple-combination treatments

AU - Epstein, Benjamin J.

AU - Shah, Niren K.

AU - Hart, Nancy

PY - 2013/1/1

Y1 - 2013/1/1

N2 - The objective of this review is to evaluate the role of fixed-dose triple-combination therapy for the management of hypertension. An assessment of clinical trials showed that half the patients with hypertension have uncontrolled blood pressure (BP), with underlying factors including therapeutic inertia and poor patient adherence. Many patients will require three antihypertensive agents to achieve BP goals, and current guidelines recommend combining drugs with complementary mechanisms of action. Three single-pill triple-combination treatments are available and each includes an agent affecting the renin-angiotensin-aldosterone pathway (either a direct renin inhibitor or an angiotensin II receptor blocker) in combination with a calcium channel blocker and diuretic. These triple-combination therapies consistently demonstrated significantly greater BP reduction relative to the component dual combinations, with BP reductions documented across a range of patient populations. Triple-combination treatments were well tolerated in all clinical trials reviewed. The use of single-pill, triple-combination antihypertensive therapy has been shown to be an effective, well-tolerated, and convenient treatment strategy that can help patients achieve BP control.

AB - The objective of this review is to evaluate the role of fixed-dose triple-combination therapy for the management of hypertension. An assessment of clinical trials showed that half the patients with hypertension have uncontrolled blood pressure (BP), with underlying factors including therapeutic inertia and poor patient adherence. Many patients will require three antihypertensive agents to achieve BP goals, and current guidelines recommend combining drugs with complementary mechanisms of action. Three single-pill triple-combination treatments are available and each includes an agent affecting the renin-angiotensin-aldosterone pathway (either a direct renin inhibitor or an angiotensin II receptor blocker) in combination with a calcium channel blocker and diuretic. These triple-combination therapies consistently demonstrated significantly greater BP reduction relative to the component dual combinations, with BP reductions documented across a range of patient populations. Triple-combination treatments were well tolerated in all clinical trials reviewed. The use of single-pill, triple-combination antihypertensive therapy has been shown to be an effective, well-tolerated, and convenient treatment strategy that can help patients achieve BP control.

UR - http://www.scopus.com/inward/record.url?scp=84886897748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886897748&partnerID=8YFLogxK

U2 - 10.1177/1753944713498638

DO - 10.1177/1753944713498638

M3 - Article

VL - 7

SP - 246

EP - 259

JO - Therapeutic Advances in Cardiovascular Disease

JF - Therapeutic Advances in Cardiovascular Disease

SN - 1753-9447

IS - 5

ER -